6/17/2021 6:53:35 AM
Eagle Pharma Submits Response To Complete Response Letter From FDA For Vasopressin
5/3/2021 6:53:26 AM
Eagle Pharma Appoints Luciana Borio To Board
3/2/2021 6:55:01 AM
Eagle Pharma Q4 Adj. Net Income $12.8 Mln Or $0.96/shr Vs. Income Of $6.7 Mln Or $0.48/shr Prior Year
2/2/2021 7:01:04 AM
Eagle Pharma Gets Addl FDA Questions Regarding Vasopressin; Court Date Set For July 7 In Vasopressin Trial
2/1/2021 7:43:11 AM
Eagle Pharma : US Court Postpones Feb 1 Vasopressin Trial Between Eagle And Endo Par
1/11/2021 7:12:32 AM
Eagle Pharma Updates On Vasopressin Trial, Says Trial Date
Postponed To Feb. 1 From Jan. 11 Due To COVID-19 Concerns
7/27/2017 12:32:35 PM
William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY18 Estimate To 3.23 From 3.83
7/27/2017 12:32:20 PM
William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY17 Estimate To 3.29 From 3.80
7/27/2017 12:31:59 PM
William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY18 Rev. Estimate To 235.2 M From 284.1 M
7/27/2017 12:31:38 PM
William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY17 Rev. Estimate To 245.9 M From 268.0 M
7/27/2017 10:19:39 AM
RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2019 Rev. Estimate To 388.6 M From 414.6 M
7/27/2017 10:19:28 AM
RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2018 Rev. Estimate To 201.1 M From 252.3 M
7/27/2017 10:19:17 AM
RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2017 Rev. Estimate To 232.2 M From 252.2 M
7/27/2017 10:19:05 AM
RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) Q3 17 Rev. Estimate To 49.4 M From 59.4 M
7/27/2017 10:18:38 AM
RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2019 Estimate To 8.16 From 9.09
7/27/2017 10:18:28 AM
RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2018 Estimate To 2.52 From 4.36
7/27/2017 10:18:17 AM
RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2017 Estimate To 3.59 From 4.32
7/27/2017 10:18:07 AM
RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) Q3 17 Estimate To 0.71 From 1.07